Table I.
Association between SHOC2 expression and clinicopathological features of patients with breast cancer.
| Total no. | SHOC2 expression | |||
|---|---|---|---|---|
| Characteristics | 120 | Low | High | P-value |
| Age | 0.366 | |||
| ≤40 years | 35 | 7 | 28 | |
| >40 years | 85 | 25 | 60 | |
| Tumor size | 0.023 | |||
| ≤2 cm | 57 | 21 | 36 | |
| 2–5 cm | 63 | 11 | 52 | |
| Histopathological grade | <0.001 | |||
| I | 34 | 18 | 16 | |
| II | 53 | 9 | 44 | |
| III | 33 | 5 | 28 | |
| ER | 0.028 | |||
| + | 40 | 16 | 24 | |
| − | 80 | 16 | 64 | |
| PR | 0.533 | |||
| + | 68 | 20 | 48 | |
| − | 52 | 12 | 40 | |
| HER2 | 0.536 | |||
| + | 76 | 20 | 56 | |
| − | 44 | 12 | 32 | |
| Lymph node status | 0.371 | |||
| + | 86 | 21 | 65 | |
| − | 34 | 11 | 23 | |
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SHOC2, SHOC2 leucine rich repeat scaffold protein.